Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
A fresh look at Pfizer’s (PFE) recent financial performance has revived debate over whether the stock is trading below its value, with one market-focused analysis suggesting the shares could be roughly 10% undervalued.
THE APEX TIMES
THE APEX TIMES
A recent market analysis argues that pending regulatory decisions on Moderna’s vaccine pipeline could influence the stock’s next leg, even as the company continues to operate in a post-peak revenue landscape for COVID-era products.
THE APEX TIMES
A market commentary published June 20 frames Eli Lilly’s outlook as resilient, even as the drugmaker has faced challenges over the past year.
THE APEX TIMES
A Yahoo Finance report says Vertex already has a head start in non-opioid pain, while Eli Lilly has spent billions to catch up, raising the prospect that the companies could compete more directly than they do today.
THE APEX TIMES
A new stock note tied Johnson & Johnson’s valuation to an unchanged model fair value, even as analyst targets split amid competing views on the company’s pipeline progress and potential policy headwinds.
THE APEX TIMES
A Yahoo Finance-linked market note drew attention to Eli Lilly’s recent results, including a 55.5% year-over-year revenue increase and Mounjaro sales of $8.66 billion, while suggesting the stock could trade near $1,200 on a specific date.
THE APEX TIMES
A new market piece argues that, when investors grow wary of tech-led risk, large healthcare names such as Johnson & Johnson can look more resilient in the rotation toward defensives.
THE APEX TIMES
A new Yahoo Finance market note casts CVS Health as a stock that could appeal to investors focused on price trends, while offering limited specifics on the fundamental drivers behind that momentum.
THE APEX TIMES
A new market read asks whether Johnson & Johnson’s long-standing appeal as a shareholder dividend story still stacks up, even as investors increasingly weigh payout durability against sector and company-specific risks.
